Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Intercept Using NDA Extension To Prep For AdComm Review And Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is preparing for an FDA advisory committee meeting for obeticholic acid for the treatment of primary biliary cholangitis April 7, and anticipating a commercial launch in June, all while advancing its Phase III program in NASH.



Related Companies